Industry Focus
Healthcare: A Surprising Reversal for Alkermes, Celldex's Super Bad News, and J&J's Q1 in Review
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:26:07
- Mas informaciones
Informações:
Sinopsis
Alkermes’ ALKS-5461 gets a do-over, Celldex's lead drug is a bust, and the good and bad of Johnson & Johnson's Q1 earnings report. Thanks to Blooom for supporting Industry Focus. Get a month free with blooom401k.com/fool and code fool.
